ArticleFrontiers in immunology2026
Proteomic and experimental analyses reveal molecular signatures of flexural atopic dermatitis in antecubital and popliteal fossae and the therapeutic effect of Aida lotion.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The mechanisms underlying the predilection of atopic dermatitis for the antecubital and popliteal fossae remain unexplored. This preliminary exploratory study aimed to characterize the proteomic features of typical flexural atopic dermatitis lesions using proteomics integrated with animal model validation and to clarify the therapeutic mechanisms of Aida lotion. Methods: We recruited five patients with atopic dermatitis. Skin scale samples were collected from the flexural side of the antecubital and popliteal areas as the observation group, while samples from the corresponding extensor sides were used as the control group. Stratum corneum specimens were analyzed using ultra-sensitive proteomic techniques and bioinformatics to screen for differentially expressed proteins. Key candidate proteins were then validated in an atopic dermatitis mouse model to further explore the therapeutic mechanisms of Aida lotion. Results: A total of 712 differential proteins were identified. GO analysis indicated enrichment in pathways related to DNA replication, proteasome regulation, and myosin V binding. KEGG pathway analysis highlighted the importance of the PPAR and MAPK signaling pathways in the site-specific prevalence of atopic dermatitis. Key differentially expressed proteins including CYP27A1, CPT1A, FABP5 in the PPAR pathway and MAP2K3, MAP2K1, HRAS in the MAPK pathway, showed the highest fold changes. Animal experiments showed that atopic dermatitis induction increased SCORAD scores, edema, and inflammatory infiltration. Additionally, the expression levels of CPT1A, FABP5, MAP2K3, MAP2K1, and HRAS were upregulated, whereas the expression of CYP27A1 was downregulated, which was consistent with the proteomic findings, indicating that these targets have been validated as key proteins associated with the molecular pathology of flexural atopic dermatitis lesions in antecubital and popliteal fossa regions. Treatment with Aida lotion reversed these changes by downregulating CPT1A, FABP5, MAP2K3, MAP2K1, and HRAS, and upregulating CYP27A1, thereby alleviating dermatitis symptoms and reducing inflammatory and mast cell infiltration. Discussion: These findings identify CYP27A1, CPT1A, FABP5, MAP2K3, MAP2K1, and HRAS are prominent molecular signatures of atopic dermatitis in the antecubital and popliteal fossae. Aida lotion exerts therapeutic effects by modulating these key proteins and associated pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.